Laxmi Dental Ltd (LAXMIDENTL)
🎯 Key Takeaways
- Laxmi Dental Limited is in a phase of strategic expansion and operational scaling, marked by strong top-line growth and margin improvement in Q1 FY27, driven by demand in Dental Laboratory and Aligner Solutions segments. The company is actively advancing its IPO-related capital allocation, including land acquisition and plant construction, while issuing minor ESOP shares.
- Revenue grew 1% QoQ to ₹75 in Q1FY27.
- ⚠️ 1) The company’s growth is increasingly tied to international markets, exposing it to currency volatility and geopolitical risks, which are not yet qu
- Market Cap
- ₹1,060
- P/E Ratio
- 34.1
- P/B Ratio
- 4.36
- ROE
- 12.7%
- ROCE
- 12.7%
- Debt/Equity
- 0.05
- Promoter
- 41.8%
📖 The Story
Laxmi Dental Limited is in a phase of strategic expansion and operational scaling, marked by strong top-line growth and margin improvement in Q1 FY27, driven by demand in Dental Laboratory and Aligner Solutions segments. The company is actively advancing its IPO-related capital allocation, including land acquisition and plant construction, while issuing minor ESOP shares. Despite a 42.59% YoY decline in 1-year return, recent quarterly performance shows a clear recovery trajectory, suggesting a turnaround from prior period pressures to renewed growth momentum.
📰 What's Happening
In Q1 FY27, Laxmi Dental reported consolidated revenue of ₹747.0 crores, up 13.9% YoY, with PAT rising 23.8% to ₹103.2 crores and EBITDA margin expanding to 19.2%. Management highlighted growth in Dental Laboratory (+23.5% YoY) and Aligner Solutions (+28.6% YoY), attributing it to product mix improvements and international demand. The Board approved ESOP allotment of 7,911 shares and proposed a variation in IPO fund utilization to include land acquisition and plant construction, extending timelines to FY27-FY28, pending shareholder approval. ICRA’s monitoring confirmed no deviations in IPO proceeds utilization, aligning with offer document disclosures. The company is also pursuing a subsidiary merger and has completed land purchase in Palghar.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 72 | 66 | 74 | 75 |
| Operating Profit | 7 | 3 | 9 | 10 |
| OPM % | 10.1% | 4.2% | 12.3% | 13.4% |
| Net Profit | 8 | 1 | 11 | 10 |
| EPS | ₹1.59 | ₹0.37 | ₹1.83 | ₹1.87 |
The company’s financial trajectory shows a clear inflection point: revenue has grown from ₹66 crores in Dec 2025 to ₹75 crores in Jun 2026, with operating profit margin expanding from 4.2% to 13.4% over the same period. This improvement aligns with management’s focus on higher-margin segments like Aligner Solutions and international markets. PAT and EPS have also risen consistently from ₹1 crore in Dec 2025 to ₹11 crores in Mar 2026, indicating improved operational efficiency and scaling benefits. The trend supports management’s narrative of margin expansion driven by product mix and automation investments.
🔮 Management Outlook & What's Next
Management did not provide formal forward guidance in the Q1 FY27 financial results filing. However, strategic priorities were reiterated through actions: continued investment in U.S. leadership, AI automation, and expansion into manufacturing via land acquisition and plant construction. The proposed subsidiary merger and IPO fund variation signal long-term structural growth ambitions. While no revenue or margin targets were disclosed, the emphasis on international demand and product innovation suggests expectations of sustained growth, contingent on shareholder approval of IPO fund reallocation.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 11 | 6 | 11 | 11 |
| Reserves | 198 | 61 | 232 | 218 |
| Borrowings | 11 | 47 | 13 | 9 |
| Total Liabilities | 285 | 158 | 294 | 266 |
| Fixed Assets | 51 | 45 | 59 | 49 |
| Investments | 10 | 7 | 27 | 15 |
| Total Assets | 285 | 158 | 294 | 266 |
The balance sheet reflects a low-debt profile with D/E of 0.05 and minimal borrowings of ₹13 crores as of Mar 2026, indicating conservative capital structure. Equity and reserves have remained stable around ₹11 crores and ₹232 crores respectively, while total assets grew to ₹294 crores, suggesting asset base expansion without significant leverage. Cash flow shows strong operating cash flow of ₹44 crores in Mar 2025, supporting internal funding of operations and IPO-related expenditures. The company is not over-leveraged and appears to be funding growth through retained earnings and IPO proceeds, with no urgent financing needs disclosed.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +44 | -5 |
| Investing | -29 | -80 |
| Financing | +111 | -18 |
| Net Cash Flow | +125 | -102 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 41.7% | 41.7% | 41.8% | 41.8% |
| FII | 32.4% | 32.5% | 31.2% | 30.1% |
| DII | 11.8% | 10.8% | 10.5% | 10.9% |
| Public | 9.3% | 10.2% | 11.5% | 11.8% |
| # Shareholders | 37,909 | 38,635 | 38,161 | 36,937 |
Institutional investor interest has declined slightly, with FII holding dropping from 32.45% in Q3FY26 to 30.1% in Q1FY27, while DII holdings stabilized around 10.8%. Promoter holding remains steady near 41.7%. The increase in shareholder count from 37,909 to 36,937 suggests broader retail participation. No significant selling by promoters or institutions is evident, but the modest decline in FII allocation may reflect profit booking or re-rating concerns despite strong quarterly results. The rising number of shareholders could indicate retail interest following recent disclosures.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | — | 0.60 |
| MAXHEALTH | 97,412 | 66.8 | 14.4% | — | 0.27 |
| MANIPALHOS | 94,970 | — | — | — | 1.25 |
| ASTERDM | 65,184 | 121.0 | 12.9% | — | 0.17 |
| FORTIS | 62,782 | 59.9 | 13.3% | — | 0.29 |
| MEDANTA | 38,551 | 69.3 | 21.9% | — | 0.10 |
| NH | 37,160 | 45.3 | 13.7% | — | 1.07 |
| LALPATHLAB | 32,549 | 46.8 | 29.6% | — | 0.00 |
| KIMS | 32,181 | 150.2 | 9.7% | — | 1.44 |
| POLYMED | 16,587 | 52.6 | 15.1% | — | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) The company’s growth is increasingly tied to international markets, exposing it to currency volatility and geopolitical risks, which are not yet quantified in disclosures. 2) The IPO fund variation for land acquisition and plant construction introduces execution risk — delays or cost overruns could impact timelines and capital efficiency. 3) Despite margin expansion, EBITDA margin remains below global peers in aligner solutions, raising questions about sustainable competitive advantage. 4) ESOP dilution, though minor, adds to share count and could pressure EPS if growth slows post-expansion.
📋 Recent Filings
- 🟡 Board Meeting2026-09-25Laxmi Dental held its 22nd AGM on September 25, 2026 via video conference, approving audited standalone and consolidated financial statements for FY20…
- Announcement2026-09-25Laxmi Dental Ltd announced that its trading window closes on October 1, 2026, ahead of Q2 results, restricting insider trading until 48 hours after fi…
- 🔴 Announcement2026-09-23Laxmi Dental Ltd announced its schedule for a non-deal roadshow on September 28, 2026, to meet institutional investors and analysts in Mumbai, discuss…
- 🔴 Announcement2026-09-23Laxmi Dental Ltd announced its schedule for a non-deal roadshow on September 29, 2026, to meet analysts and institutional investors in Mumbai, discuss…
- 🔴 Announcement2026-09-18Laxmi Dental Ltd received regulatory approval to list and trade 7,911 equity shares under its 2024 Employee Stock Option Scheme, effective September 1…
- 🔴 Announcement2026-09-04Laxmi Dental Limited announced its schedule of analyst and institutional investor meetings at its Mumbai manufacturing facility on September 9-10, 202…
- 🟡 Board Meeting2026-09-03Laxmi Dental Ltd announces its 22nd AGM on September 25, 2026, via video conferencing and e-voting, with shareholders required to register by Septembe…
- 🔴 annual report2026-09-03Laxmi Dental Ltd convened its 22nd AGM on September 25, 2026, via video conference, to approve FY2026 financial statements, reappoint Rajesh Khakhar a…
- 🔴 Announcement2026-08-31Laxmi Dental Limited received regulatory approval to list and trade 59,360 equity shares issued under its 2024 Employee Stock Option Scheme, with NSE …
- 🔴 Corporate Action2026-08-27Laxmi Dental announced on August 27, 2026, the allotment of 7,911 equity shares of INR 2 each under its 2024 ESOP to eligible employees, increasing pa…
🧠 Analyst's Read
Laxmi Dental is transitioning from stabilization to growth, supported by strong quarterly momentum, improving margins, and strategic capital allocation toward manufacturing and global expansion. The lack of forward guidance limits near-term visibility, but the alignment between management actions and financial trends suggests a coherent growth narrative. Investors should monitor shareholder approval of IPO fund variation and subsequent updates on plant timelines, as these will be critical catalysts for future performance.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LAXMIDENTL files new disclosures
Track LAXMIDENTL filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LAXMIDENTL — FreeFree account · 2 AI queries/day